Article
Targeting DESI2 as a Novel Therapeutic Strategy for JAK2-Mutant Leukemias.
Advanced science (Weinheim, Baden-Wurttemberg, Germany) - 1 Feb 2026
Mei Husheng, Wen Wuqiang, Zhang Wenjun, Zhang Shujing, Sun Ting, Li Guiming, Zhang Jing, Qi Shuang, Zhou Jie, Li Bing, Zhao Yunshuo, Chen Xiaotong, Li Bowen, Xue Yiying, Lu Wang, Sun Yanli, Wang Jingyao, Shan Hengyue, Zhang Shengzhe, Huang Yushan, Chen Yisa, Wang Wenchao, Liu Qingsong, Lu Wenchao, Tan Li, Ding Yi, Fu Jianfei, Long Jun, Zhang Lei, Zhao Baobing, Liang Aibin, Jiang Baishan, Yang Jing
Abstract excerpt
The JAK2-V617F mutation is the most common genetic alteration in myeloproliferative neoplasms (MPN), which can progress to secondary acute myeloid leukemia (sAML), a chemotherapy-resistant disease with limited treatment options and a poor prognosis. Although the JAK1/2 inhibitor Ruxolitinib is clinically approved, its efficacy is limited by toxicity to normal cells and the development of drug resistance. Here,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.